Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Clinical-stage biotech company Neurizon highlights neuroprotective effect of NUZ-001 in TDP-43 disease model. ... Read More ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective candidate, NUZ-001, using Tessara Therapeutics' 3D human brain model. The ...

“All the indications have high unmet need and large markets,” Jain said. Neurizon Therapeutics (ASX:NUZ) is targeting amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Neurizon Therapeutics (ASX:NUZ) has confirmed its lead drug candidate has neuroprotective potential in an independent study. The study’s authors noted that NUZ-001’s cell survival effect was ...